Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
Commentary|Articles|August 15, 2024
Effective Strategies to Enhance Medicare Advantage Star Ratings
Author(s)Brooke McCormick
On this episode of Managed Care Cast, we discuss strategies to improve 2025 Medicare Advantage Star ratings, especially for smaller plans, with Marge Ciancetta, the product manager of Cotiviti's Star Intelligence solution.
Advertisement
On this episode of Managed Care Cast, we're talking with Marge Ciancetta, the product manager of Cotiviti's
We discuss all things Star Ratings, including their importance, how they are calculated, and their impact on plans in 2024. Looking ahead, we also discussed strategies to improve ratings for 2025, especially for smaller plans.
Listen above or on one of these podcast services:
Advertisement
Related to this article
As National Family Caregivers Month begins, AJMC presents coverage from PCOC's first-ever panel on caregiving, where participants discuss demands on family members who are the “eyes and ears” when patients receive CAR T, bispecific, or transplant treatments.
Facing steep 2027 cost increases, employers are narrowing obesity drug coverage, while direct-to-employer models let them cap what they spend.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
HHS enforcement discretion lets state pharmacies compound BPC-157 and other peptides amid rulemaking and legal challenges.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push menin inhibitor starts into the clinic, emergency department (ED) physicians may not recognize differentiation syndrome, and capitated insurance contracts steer some patients with acute myeloid leukemia away from academic centers.
Cost and access, not side effects, drive GLP-1 discontinuation, and obesity should be covered like diabetes, says Fatima Cody Stanford, MD.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
3
Birth Weight, Childhood Weight Gain Linked to Non-Hodgkin Lymphoma Risk
4
Kidney Week 2026 Recap: IgAN Advances, Value-Based Care, CKD Care Gaps
5